Suchergebnisse
10
Alles
Such-Filter
Tag
orphan drug
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
25. Februar 2025 09:25 ET
|
Trethera Corporation
LOS ANGELES, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through...
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
24. Februar 2025 08:30 ET
|
Biodexa Pharmaceuticals PLC
February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in...
The FDA (Food and Drug Administration) Drug Approval Process Online Training Course (June 11-12, 2025): Essential Strategies for INDs, NDAs, ANDAs, and 505(b)(2) Applications
06. Februar 2025 12:43 ET
|
Research and Markets
Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
The Impact and Trends of Review Designations in the Pharmaceutical Industry
05. Februar 2025 09:56 ET
|
Research and Markets
Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates...
FDA (Food and Drug Administration) Drug Approval Process Training Course: Practical Insights into FDA Requirements and Up to Date Developments (ONLINE EVENT: February 24-25, 2025)
30. Januar 2025 07:54 ET
|
Research and Markets
Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
Orphan Drugs Strategic Business Report 2024-2030: Biologics, Oncology & Hospital Pharmacies - The Pulsating Segments of Global Market
22. Januar 2025 05:51 ET
|
Research and Markets
Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) -- The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Orphan Drugs was...
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
03. Dezember 2024 06:00 ET
|
Priothera
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Mocravimod is the only S1P receptor...
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND)
21. November 2024 06:08 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting
14. November 2024 16:45 ET
|
Osteal Therapeutics
DALLAS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug Designation for Congenital Myasthenic Syndrome
24. Oktober 2024 12:50 ET
|
Muscular Dystrophy Association
New York, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly announces that its groundbreaking MDA Kickstart program has received both an FDA Rare Pediatric Disease...